Samir M. Gharib
Known title: President & CFOCIK: 0001533302
Associated companies
Transaction History
| SPRB | ▼ Sell | Tax Withholding | 178 | $14K | 12/15/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 513 | $0 | 12/15/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 184 | $15K | 12/15/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 496 | $0 | 12/15/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 1,900 | $0 | 12/11/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 680 | $60K | 12/11/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 514 | $0 | 12/10/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 184 | $16K | 12/10/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 2,053 | $0 | 10/20/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 661 | $98K | 10/20/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 37,250 | $0 | 12/16/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 38,500 | $0 | 12/16/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 13,737 | $5K | 12/16/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 13,291 | $5K | 12/16/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 154,000 | $0 | 12/10/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 54,948 | $30K | 12/10/2024 | View on chart |
| SPRB | ▲ Buy | Grant | 11,255 | $11K | 12/29/2023 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 12,882 | $21K | 12/15/2023 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 75,000 | $0 | 12/15/2023 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 23,213 | $39K | 12/15/2023 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 37,250 | $0 | 12/15/2023 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 75,000 | — | 6/30/2023 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 25,936 | $56K | 6/30/2023 | View on chart |
| SPRB | ▲ Buy | Grant | 10,484 | $10K | 6/30/2023 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 15,293 | $18K | 1/3/2023 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 37,500 | — | 1/3/2023 | View on chart |
| SPRB | ▲ Buy | Grant | 1 | $1 | 12/30/2022 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 12,968 | $23K | 6/30/2022 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 37,500 | — | 6/30/2022 | View on chart |
| SPRB | ▲ Buy | Grant | 5,446 | $8K | 6/30/2022 | View on chart |
| SPRB | ▼ Sell | Other | 2,220 | $8K | 12/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Citizens Maintains $144 Target for Spruce Biosciences
Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.
Citizens Maintains $144 Target for Spruce Biosciences. Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.